ESMO 2014: Phase II Study 19 quality of life study of olaparib in ovarian cancer

At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Susan Galbraith (Vice-President Oncology, AstraZeneca) discusses the Study 19 phase II quality of life study of maintenance treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib, in patients with relapsed, high-grade, platinum-sensitive ovarian cancer.

Year of Production:
Running Time:
Color/Sound:

2015
01:25
Color/Sound

Comments are closed.